Ironwood Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Amounts are in U.S. dollars. Ironwood is a gastrointestinal therapeutics company whose revenue is primarily tied to LINZESS collaboration arrangements, particularly U.S. sales shared with AbbVie.
Financial performance
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $74.9 million | $104.1 million |
| Research and development expense | $25.8 million | $12.8 million |
| Selling, general and administrative expense | $37.6 million | $31.1 million |
| Operating income | $11.0 million | $60.1 million |
| Net income (loss) | $(4.2) million | $45.7 million |
| Basic and diluted EPS | $(0.03) | $0.30 basic; $0.25 diluted |
| Operating cash flow | $45.0 million | $80.2 million |
Operating margin was approximately 14.7%, compared with 57.8% in Q1 2023. The filing does not present a conventional gross margin for these collaboration-based revenues.
Liquidity, debt and balance sheet
- Cash and cash equivalents were $121.5 million at March 31, 2024, up from $92.2 million at year-end. Operating cash flow was $45.0 million; the company repaid $25.0 million on its revolver and ended the quarter with $275.0 million drawn.
- Debt principal comprised $400.0 million of convertible notes and $275.0 million under a $500.0 million secured revolving facility. The 2024 notes mature June 15, 2024; the 2026 notes mature June 15, 2026. The filing reports $398.3 million carrying value for the notes.
- Current assets were $208.2 million and current liabilities $252.4 million, a $44.3 million working-capital deficit. Current liabilities include $199.8 million carrying value of the 2024 notes.
- Stockholders’ deficit was $330.5 million. The company reported compliance with the revolving facility’s financial covenants at quarter-end.
Material changes and unusual items
- Revenue fell $29.2 million year over year, principally reflecting a $29.9 million decline in Ironwood’s share of U.S. LINZESS profits. A $38.0 million reduction to collaboration revenue reflected revised estimates of governmental and contractual rebate reserves, including $30.0 million based on information received from AbbVie after the quarterly settlement process. The company said that without these estimate changes, Q1 EPS would have been $0.14 basic and $0.12 diluted.
- Excluding those estimate changes, U.S. LINZESS profit share increased nominally: higher prescription demand and channel inventory effects were partly offset by lower net price, according to management.
- R&D expense increased $13.0 million, primarily due to $19.3 million of apraglutide costs, partly offset by a $4.8 million reduction from settlement of a license-related contract liability. SG&A rose $6.5 million, including acquired VectivBio operating costs.
- Other income and expense swung from $5.8 million of net income in Q1 2023 to $6.1 million of net expense in Q1 2024. Higher financing costs and lower investment income were the main drivers, following the acquisition-related borrowing and lower cash balances.
Outlook, developments and risks
- Management expects cash on hand and operating inflows to cover projected needs for at least 12 months from issuance of the financial statements, while cautioning that actual cash use and results could differ from forecasts. No specific full-year revenue or earnings guidance is provided.
- Ironwood reported positive topline results from the pivotal Phase III STARS trial of apraglutide in adults with short bowel syndrome with intestinal failure and plans to submit an NDA and other regulatory filings. Positive primary results through Day 91 were also reported for the Phase II STARGAZE trial in gastrointestinal acute graft-versus-host disease; follow-up continues.
- For CNP-104, the partner’s study enrollment is complete and topline data was expected in Q3 2024. Ironwood is continuing a Phase II proof-of-concept study of IW-3300 in interstitial cystitis/bladder pain syndrome.
- Key risks include dependence on AbbVie and U.S. LINZESS economics; rebate and sales-reserve estimate changes; clinical, regulatory and commercialization uncertainty for apraglutide and pipeline candidates; competition, reimbursement and manufacturing risks; and substantial debt and associated interest costs. The company also noted that VectivBio was still being integrated into internal controls.
Important facts for investors to verify
- How the $38.0 million collaboration revenue adjustment was calculated, including the $30.0 million post-settlement information from AbbVie and the potential for further reserve revisions.
- Repayment, refinancing or other settlement plans for the $200.0 million 2024 notes due June 15, 2024, and the related effect on cash and liquidity.
- Progress and timing of apraglutide regulatory submissions following STARS, and the full follow-up results from STARGAZE.
- Whether LINZESS demand, net pricing, rebates and channel inventory support future collaboration revenue and cash generation.
- Revolver covenant headroom, borrowing costs and cash needs as pipeline investment continues.